Pharmacologic resistance in colorectal cancer: A review

William A. Hammond, Abhisek Swaika, Kabir Mody

Research output: Contribution to journalReview articlepeer-review

205 Scopus citations


Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

Original languageEnglish (US)
Pages (from-to)57-84
Number of pages28
JournalTherapeutic Advances in Medical Oncology
Issue number1
StatePublished - Jan 2016


  • Colon adenocarcinoma
  • Colon cancer
  • Resistance

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Pharmacologic resistance in colorectal cancer: A review'. Together they form a unique fingerprint.

Cite this